Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Aug;39(8):1726–1730. doi: 10.1128/aac.39.8.1726

New system based on site-directed mutagenesis for highly accurate comparison of resistance levels conferred by SHV beta-lactamases.

M T Nüesch-Inderbinen 1, H Hächler 1, F H Kayser 1
PMCID: PMC162816  PMID: 7486909

Abstract

We developed a system based on site-directed mutagenesis that allows a precise comparison of SHV enzymes under isogenic conditions. In addition, the influences of two different, naturally occurring promoters were examined for each SHV derivative. The system comprised two separately cloned DNA fragments, each the size of 3.6 kb. Both fragments encoded an SHV gene originating from clinical isolates but with different promoters. The structural genes were made identical by site-directed mutagenesis. Other mutations were then introduced into both fragments by means of site-directed mutagenesis, resulting in the SHV derivatives SHV-1, SHV-2, SHV-2a, SHV-3, and SHV-5. The amino acid exchange of glutamic acid at position 235 for lysine in SHV-5 resulted in the highest resistance levels. SHV-3, differing from SHV-2 by the exchange of arginine at position 201 for leucine and previously described as indistinguishable from SHV-2, was shown to cause slightly higher resistance to ceftazidime and lower resistance to ceftriaxone, cefotaxime, and cefepime than SHV-2. The point mutation in SHV-2a, with the leucine-to-glutamine replacement at the unusual position 31, previously considered almost insignificant, proved to increase resistance to ceftazidime but reduced the MICs of all other cephalosporins tested when compared with those for SHV-2. For all clones harboring SHV derivatives, resistance was increased by a stronger promoter, in some cases masking the effect of the point mutation itself and demonstrating the importance of regulatory mechanisms of resistance.

Full Text

The Full Text of this article is available as a PDF (374.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambler R. P. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980 May 16;289(1036):321–331. doi: 10.1098/rstb.1980.0049. [DOI] [PubMed] [Google Scholar]
  2. Arlet G., Rouveau M., Bengoufa D., Nicolas M. H., Philippon A. Novel transferable extended-spectrum beta-lactamase (SHV-6) from Klebsiella pneumoniae conferring selective resistance to ceftazidime. FEMS Microbiol Lett. 1991 Jun 1;65(1):57–62. doi: 10.1016/0378-1097(91)90471-l. [DOI] [PubMed] [Google Scholar]
  3. Bradford P. A., Urban C., Jaiswal A., Mariano N., Rasmussen B. A., Projan S. J., Rahal J. J., Bush K. SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother. 1995 Apr;39(4):899–905. doi: 10.1128/aac.39.4.899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buré A., Legrand P., Arlet G., Jarlier V., Paul G., Philippon A. Dissemination in five French hospitals of Klebsiella pneumoniae serotype K25 harbouring a new transferable enzymatic resistance to third generation cephalosporins and aztreonam. Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):780–782. doi: 10.1007/BF01975048. [DOI] [PubMed] [Google Scholar]
  5. Gutmann L., Ferré B., Goldstein F. W., Rizk N., Pinto-Schuster E., Acar J. F., Collatz E. SHV-5, a novel SHV-type beta-lactamase that hydrolyzes broad-spectrum cephalosporins and monobactams. Antimicrob Agents Chemother. 1989 Jun;33(6):951–956. doi: 10.1128/aac.33.6.951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol. 1983 Jun 5;166(4):557–580. doi: 10.1016/s0022-2836(83)80284-8. [DOI] [PubMed] [Google Scholar]
  7. Hawley D. K., McClure W. R. Compilation and analysis of Escherichia coli promoter DNA sequences. Nucleic Acids Res. 1983 Apr 25;11(8):2237–2255. doi: 10.1093/nar/11.8.2237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Herzberg O., Moult J. Bacterial resistance to beta-lactam antibiotics: crystal structure of beta-lactamase from Staphylococcus aureus PC1 at 2.5 A resolution. Science. 1987 May 8;236(4802):694–701. doi: 10.1126/science.3107125. [DOI] [PubMed] [Google Scholar]
  9. Huletsky A., Knox J. R., Levesque R. C. Role of Ser-238 and Lys-240 in the hydrolysis of third-generation cephalosporins by SHV-type beta-lactamases probed by site-directed mutagenesis and three-dimensional modeling. J Biol Chem. 1993 Feb 15;268(5):3690–3697. [PubMed] [Google Scholar]
  10. Jacoby G. A., Carreras I. Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1990 May;34(5):858–862. doi: 10.1128/aac.34.5.858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jacoby G. A., Medeiros A. A. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991 Sep;35(9):1697–1704. doi: 10.1128/aac.35.9.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Katsanis G., Jacoby G. The frequency of extended-spectrum beta-lactamases in isolates of Klebsiella pneumoniae. J Antimicrob Chemother. 1992 Mar;29(3):345–346. doi: 10.1093/jac/29.3.345. [DOI] [PubMed] [Google Scholar]
  13. Kayser F. H., Morenzoni G., Homberger F. Activity of cefoperazone against ampicillin-resistant bacteria in agar and broth dilution tests. Antimicrob Agents Chemother. 1982 Jul;22(1):15–22. doi: 10.1128/aac.22.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kliebe C., Nies B. A., Meyer J. F., Tolxdorff-Neutzling R. M., Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother. 1985 Aug;28(2):302–307. doi: 10.1128/aac.28.2.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Labia R., Morand A., Tiwari K., Sirot J., Sirot D., Petit A. Interactions of new plasmid-mediated beta-lactamases with third-generation cephalosporins. Rev Infect Dis. 1988 Jul-Aug;10(4):885–891. doi: 10.1093/clinids/10.4.885. [DOI] [PubMed] [Google Scholar]
  16. Lenfant F., Petit A., Labia R., Maveyraud L., Samama J. P., Masson J. M. Site-directed mutagenesis of beta-lactamase TEM-1. Investigating the potential role of specific residues on the activity of Pseudomonas-specific enzymes. Eur J Biochem. 1993 Nov 1;217(3):939–946. doi: 10.1111/j.1432-1033.1993.tb18324.x. [DOI] [PubMed] [Google Scholar]
  17. Medeiros A. A. Beta-lactamases. Br Med Bull. 1984 Jan;40(1):18–27. doi: 10.1093/oxfordjournals.bmb.a071942. [DOI] [PubMed] [Google Scholar]
  18. Nicolas M. H., Jarlier V., Honore N., Philippon A., Cole S. T. Molecular characterization of the gene encoding SHV-3 beta-lactamase responsible for transferable cefotaxime resistance in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother. 1989 Dec;33(12):2096–2100. doi: 10.1128/aac.33.12.2096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Palzkill T., Botstein D. Identification of amino acid substitutions that alter the substrate specificity of TEM-1 beta-lactamase. J Bacteriol. 1992 Aug;174(16):5237–5243. doi: 10.1128/jb.174.16.5237-5243.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Petit A., Ben Yaghlane-Bouslama H., Sofer L., Labia R. Does high level production of SHV-type penicillinase confer resistance to ceftazidime in Enterobacteriaceae? FEMS Microbiol Lett. 1992 Apr 1;71(1):89–94. doi: 10.1016/0378-1097(92)90547-2. [DOI] [PubMed] [Google Scholar]
  21. Philippon A., Labia R., Jacoby G. Extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1989 Aug;33(8):1131–1136. doi: 10.1128/aac.33.8.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Podbielski A., Schönling J., Melzer B., Haase G. Different promoters of SHV-2 and SHV-2a beta-lactamase lead to diverse levels of cefotaxime resistance in their bacterial producers. J Gen Microbiol. 1991 Jul;137(7):1667–1675. doi: 10.1099/00221287-137-7-1667. [DOI] [PubMed] [Google Scholar]
  23. Podbielski A., Schönling J., Melzer B., Warnatz K. Molecular cloning and nucleotide sequence of a new plasmid-coded Klebsiella pneumoniae beta-lactamase gene (SHV-2a) responsible for high-level cefotaxime resistance. Zentralbl Bakteriol. 1991 Aug;275(3):369–373. doi: 10.1016/s0934-8840(11)80302-6. [DOI] [PubMed] [Google Scholar]
  24. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sougakoff W., Petit A., Goussard S., Sirot D., Bure A., Courvalin P. Characterization of the plasmid genes blaT-4 and blaT-5 which encode the broad-spectrum beta-lactamases TEM-4 and TEM-5 in enterobacteriaceae. Gene. 1989 May 30;78(2):339–348. doi: 10.1016/0378-1119(89)90236-9. [DOI] [PubMed] [Google Scholar]
  26. Sutcliffe J. G. Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3737–3741. doi: 10.1073/pnas.75.8.3737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Yanisch-Perron C., Vieira J., Messing J. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene. 1985;33(1):103–119. doi: 10.1016/0378-1119(85)90120-9. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES